Q2 FY2026 EarningsQ2 FY26 beat consensus across key top-line and margin metrics: revenue $51.4M vs. $49.5M expected, and gross margin 40.1% vs. 36.6%. The performance was driven by an 11.5% YoY increase in TriLink revenue, fueled by RUO raw materials and GMP consumables, alongside successful cost reductions from the 2025 Corporate Realignment Plan. Despite a GAAP EPS of -$0.08 missing the mean estimate of -$0.10, the company achieved a positive Adjusted EBITDA of $8.7M, a significant recovery from the prior year's $10.4M loss.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Maravai LifeSciences(MRVI) the Revenue is 51.44 M (+8.53%), Beat estimate;the EBIT is -3.108 M (+86.81%), Beat estimate;the EPS is -0.08 (+70.37%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.05B8.53%
0.05B2.71%
+0.00B5.82%
EBITExceed expectations
-0.00B86.81%
-0.01B57.22%
+0.01B29.59%
EPSExceed expectations
-0.0870.37%
-0.162.96%
+0.02007.41%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf